Project Updates and Milestones news (page 3)

• 

  21 October 2025

  MOL Danube Refinery Fire Incident

  A fire at the Danube Refinery's AV3 plant was contained. No injuries reported. Authorities monitor air quality. Hungarian fuel supply remains secure. Investigation and damage assessment ongoing.
• 

  21 October 2025

  Port of Antwerp-Bruges: Mixed Results Amid Volatile Market

  Container traffic stabilizes, bulk declines due to global uncertainty. US tariffs impact exports. European chemical sector faces challenges. RoRo and US trade show growth.
• 

  20 October 2025

  Johnson & Johnson's INLEXZO™ and Cetrelimab Show Promising Pre-Surgical Results in Bladder Cancer

  Phase 2b study shows INLEXZO™ plus cetrelimab achieves significant pathologic response rates in muscle invasive bladder cancer patients ineligible for platinum-based chemotherapy.
• 

  20 October 2025

  ORLEN Enhances Hydrogen Capabilities in Pomerania with Expert Support

  Amber Hydrogen Valley receives expert advisory to optimize costs and guide it to final investment decision, aiming to build a full hydrogen value chain in Pomerania.
• 

  20 October 2025

  WuXi Biologics Receives 2025 Global Customer Value Leadership Award from Frost & Sullivan

  Recognized for innovation and operational excellence, the company supports 864 projects, achieving a 98% success rate in manufacturing and passing 44 global regulatory inspections.
• 

  20 October 2025

  bp Announces Discovery in Namibia's Orange Basin

  Volans-1X well in Orange Basin finds 26m of gas condensate reservoirs with high CGR. Third major 2025 discovery for Azule Energy partners. Further evaluation ongoing.

• 

  20 October 2025

  Roche's Gazyva Approved by FDA for Lupus Nephritis Treatment

  FDA approves Gazyva for lupus nephritis, showing superior results in trials, offering a new treatment option to prevent kidney disease progression.
• 

  19 October 2025

  Johnson & Johnson's Subcutaneous Amivantamab Shows 45% Response Rate in Head and Neck Cancer

  Subcutaneous amivantamab offers rapid, durable responses in head and neck cancer, with 82% tumor shrinkage and a median response duration of 7.2 months.
• 

  19 October 2025

  Raludotatug Deruxtecan Shows 50.5% Response in Platinum-Resistant Ovarian Cancer, Reports Daiichi Sankyo and Merck

  Raludotatug deruxtecan achieved a 50.5% response rate in phase 2 for platinum-resistant ovarian cancer, with a 5.6 mg/kg dose selected for phase 3.
• 

  18 October 2025

  Genmab Reports Positive Phase 1/2 Trial Results for Rina-S in Advanced Endometrial Cancer

  Rina-S shows 50% response rate in advanced endometrial cancer trial; FDA grants Breakthrough Therapy Designation.
• 

  18 October 2025

  Merck and Eisai: KEYTRUDA and LENVIMA Show 5-Year Survival Benefit in Advanced Endometrial Carcinoma

  KEYTRUDA and LENVIMA improve 5-year survival rates in advanced endometrial carcinoma compared to chemotherapy, with consistent results across patient subgroups.
• 

  18 October 2025

  Merck's KEYTRUDA Plus Chemotherapy Reduces Disease Progression Risk in Platinum-Resistant Ovarian Cancer

  KEYTRUDA with chemotherapy shows significant survival benefits in platinum-resistant ovarian cancer, leading to FDA priority review for expanded use.
• 

  17 October 2025

  FDA Approves Novo Nordisk's Oral Semaglutide for CV Risk Reduction in High-Risk Type 2 Diabetes Adults

  Oral semaglutide reduces major cardiovascular events in high-risk type 2 diabetes patients, showing a 14% risk reduction over 4 years, with consistent safety profile.
• 

  17 October 2025

  Roche's Gazyva/Gazyvaro Gains EU CHMP Nod for Lupus Nephritis

  CHMP backs Gazyva/Gazyvaro for lupus nephritis, showing superior renal response in trials. Awaiting European Commission decision.
• 

  17 October 2025

  Mitsubishi Chemical's SoarnoL EVOH Resins Approved for Recyclability in Multilayer Films

  RecyClass confirms multilayer films with up to 10% SoarnoL EVOH resins are recyclable with PE flexibles, supporting sustainable packaging and circular economy efforts.
• 

  16 October 2025

  E3 Lithium and Axens Sign MOU for Lithium Carbonate Sale and Sorbent Supply

  The MOU outlines plans for E3 to supply lithium carbonate and Axens to provide a lithium sorbent, aiming for secure supply chains and future definitive agreements.
• 

  16 October 2025

  Repsol and Forestalia Launch Major Hybrid Energy Project in Aragon

  Hybrid project in Aragon combines 818 MW power plant with 805 MW wind farms, optimizing grid use and supporting a nearby data center with renewable energy.
• 

  16 October 2025

  Johnson & Johnson's AKEEGA® Gets FDA Priority Review for BRCA-Mutated Prostate Cancer

  FDA grants Priority Review to AKEEGA® for BRCA-mutated prostate cancer, showing reduced progression risk and improved outcomes in Phase 3 study.
• 

  16 October 2025

  Merck's KEYNOTE-B96 Trial Shows Improved Survival in Platinum-Resistant Ovarian Cancer

  The trial showed improved overall survival with KEYTRUDA in platinum-resistant ovarian cancer, with consistent safety and no new signals. Results to be presented at a future medical meeting.
• 

  16 October 2025

  Sasol and Topsoe Partner on E-Fuels Plant in Germany

  A new e-fuels plant in Germany will produce 2500 tons annually, using renewable feedstocks, with €130 million funding from the German government. Completion is expected by Q4 2027.
• 

  16 October 2025

  Nobian Enhances Frankfurt Site's Energy Efficiency with Flexible Production

  The site adjusts chlor-alkali production to electricity availability, aiding grid stability and reducing costs, while maintaining safety and aiming for climate neutrality by 2040.
• 

  16 October 2025

  Nouryon Boosts China Operations with Metal Alkyls Expansion and New Innovation Center

  Nouryon invests in China to meet polymer demand, doubling triethylaluminum capacity, starting MMAO production, and opening an organic peroxides innovation center.
• 

  16 October 2025

  Equinor Begins Production at Bacalhau Field

  Bacalhau field in Brazil starts production with over 1 billion boe reserves, using advanced FPSO technology for efficient, low-emission output. Expected to create 50,000 jobs over 30 years.
• 

  15 October 2025

  Pearl Petroleum Boosts Khor Mor Gas Capacity by 50%

  KM250 project adds 250 MMscf/d capacity, increasing Khor Mor's output to 750 MMscf/d, meeting over 80% of Kurdistan's power needs. Delivered eight months ahead of schedule.
• 

  15 October 2025

  Novo Nordisk Acquires Rights to Omeros' MASP-3 Inhibitor Zaltenibart

  Zaltenibart, a MASP-3 inhibitor, targets rare blood and kidney disorders. Omeros receives up to $2.1 billion, plus royalties. Novo Nordisk plans global phase 3 trials.
• 

  15 October 2025

  Merck Reports Phase 3 Trial Data on Doravirine-Islatravir Regimen

  Phase 3 trials show minimal weight, body composition, and lipid changes with the DOR/ISL regimen in HIV-1 patients, maintaining viral suppression without resistance.
• 

  15 October 2025

  Stahl Reopens Ranipet Facility in India for Sustainable Growth

  The upgraded facility focuses on local production, innovation, and sustainability, enhancing R&D and customer collaboration in a key growth market.
• 

  14 October 2025

  Uniper Advances Green Hydrogen Production at Bad Lauchstädt

  The Bad Lauchstädt Energy Park nears completion with its 30 MW electrolyzer, set to produce 4,000 tons of green hydrogen annually, supporting Germany's energy transition.
• 

  14 October 2025

  Lhyfe Launches Germany's Largest Renewable Hydrogen Site

  Lhyfe's new site in Schwäbisch Gmünd produces 4 tons of renewable hydrogen daily, aiming to decarbonize transport and industry, supported by EU and state funding.
• 

  14 October 2025

  ECLUSE Completes Belgium's Longest Microtunnel

  The ECLUSE tunnel under the Scheldt is complete, enabling steam transport from waste-to-energy facilities to Evonik, reducing CO₂ emissions and supporting Antwerp's energy transition.